OptiBiotix Health expects revenue boost as it switches from R&D focus

Writer, Stock Market Wire
Wednesday, February 13, 2019 - 07:51

OptiBiotix Health said it had boosted its annual income as it continued to transition from an R&D business to a commercial company generating sales.

Revenue for the year through November had jumped to £541k, up from £191k on-year, with the bulk booked in the second half of the year.

'We anticipate further revenue growth in 2019 as existing deals contribute to full year revenues, and partners continue to grow sales,' the company said.


Related content

OptiBiotix Health inks distribution pact for South Africa, neighbouring countries

OptiBiotix Health said it had entered into a one-year exclusive distribution agreement with a South African partner for its consumer weight-management products in South Africa...

Wed, 18/09/2019 - 07:48


OptiBiotix Health books first-half loss as it inks more distribution pacts

Dietry supplement group for weight loss and cholesterol control OptiBiotix Health booked a first-half loss after modest sales were offset by administrative costs.

Pre-tax losses...

Wed, 28/08/2019 - 08:01


OptiBiotix Health inks distribution pact in Australia, NZ with Maxum Foods

OptiBiotix Health said it had entered into a manufacturing, supply and distribution agreement with Maxum Foods for its weight management technology in Australia and New...

Mon, 12/08/2019 - 08:01


OptiBiotix Health inks license agreement with Tenshindo in Japan

OptiBiotix Health said subsidiary ProBiotix Health had signed a non-exclusive license agreement with Tenshindo for the use of Lactobacillus plantarum in cardiovascular food supplements in...

Wed, 03/07/2019 - 07:54


OptiBiotix Health inks licencing agreement with Kappa Bioscience

OptiBiotix Health said subsidiary ProBiotix Health had signed a license agreement with Kappa Bioscience.

The agreement covered the use of OptiBiotix Health's blood pressure-reducing probiotic...

Mon, 01/07/2019 - 08:51